Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer
In recent years, there has been a wide range of treatment options for patients with metastatic HER2-positive breast cancer, resulting in the highest life expectancy for these patients among all subtypes. The addition of pertuzumab to trastuzumab and docetaxel has been shown to increase overall...
محفوظ في:
| المؤلفون الرئيسيون: | , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Russo |
| منشور في: |
Remedium Group LLC
2021-12-01
|
| سلاسل: | Медицинский совет |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.med-sovet.pro/jour/article/view/6594 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|